PMD15 Cost Utility Analysis of New Matrix Therapy Regenerating Agent (RGTA®) VS Good Wound Care for Patients with Advanced Diabetic Foot Ulcer

Abstract

Authors

S. Mesaros T. Mesaros K. Mesarosova

Full Text Cite This Article
Back to Volume 22, Supplemental S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×